Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Director departure
ALPHARMA INC (ALO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/29/2008 8-K Quarterly results
Docs: "Alpharma Reports Third Quarter 2008 EPS of $0.10"
07/30/2008 8-K Quarterly results
Docs: "Alpharma Reports Second Quarter 2008 Revenue Growth of 25% from Continuing Operations Pharmaceutical Revenue Gains Outpace Declines in Animal Health U.S. Livestock Sales"
05/05/2008 8-K Quarterly results
Docs: "Alpharma Reports First Quarter 2008 Revenue Growth of 33% from Continuing Operations"
02/26/2008 8-K Quarterly results
Docs: "Alpharma Reports Double-Digit Full Year and Fourth Quarter 2007 Revenue Growth"
10/30/2007 8-K Quarterly results
Docs: "Alpharma Reports Third Quarter 2007 EPS of $0.34 22% Revenue Growth in Pharmaceuticals, Abuse Deterrent Phase III Clinicals on Track Bridgewater, NJ October 29, 2007 Alpharma Inc. , a global specialty pharmaceutical company, announced third quarter 2007 diluted earnings per share of $0.34, versus EPS of $0.31 in the third quarter of 2006. Revenue of $175.8 million in the third quarter of 2007 increased 6.4% versus the third quarter of 2006, driven principally by gains in the company's Pharmaceuticals business. Operating income in the third quarter of 2007 was $19.7 million, a decrease of $2.5 million compared to last year's third quarter, reflecting $6.5 million of increased research and development spending, primarily related to the company's abuse-deterrent pain product platform in its P..."
08/01/2007 8-K Quarterly results
04/30/2007 8-K Quarterly results
02/27/2007 8-K Quarterly results
Docs: "Presentation of Information in this Press Release"
10/30/2006 8-K Quarterly results
Docs: "Alpharma Reports EPS From Continuing Operations of $0.31 Versus Year Ago Results of $0.10 Revenue Grows 22%; Significant Increase in Branded R&D Investment Fort Lee, NJ October 30, 2006 Alpharma Inc. , a global specialty pharmaceutical company, announced third quarter 2006 diluted earnings per share from continuing operations of $0.31 compared to $0.10 in the third quarter of 2005. EPS in the third quarter of 2005, including discontinued operations related to the company's divested generics business, was $0.34. Third quarter 2006 revenues increased $29.8 million or 22% versus 2005 to $165.3 million, driven by revenue gains in each of the company's businesses. Operating income in the third quarter of 2006 was $22.2 million versus $22.3 in 2005, and the operating margins were 13.4% in 2006 c..."
07/31/2006 8-K Quarterly results
Docs: "Alpharma Reports EPS From Continuing Operations of $0.32 Versus Year Ago Results of $0.12 Revenue Grows 16% Fort Lee, NJ July 31, 2006 Alpharma Inc. , a global specialty pharmaceutical company, announced second quarter 2006 diluted earnings per share from continuing operations of $0.32 compared to $0.12 in the second quarter of 2005. Including discontinued operations related to the company's divested generics business, EPS in the second quarter of 2006 was $0.30 versus $0.38 a year ago. Second quarter 2006 revenues increased $21.6 million or 16% versus 2005 to $159.2 million, driven primarily by 55% revenue growth in the company's Branded Pharmaceuticals business. Operating income in the second quarter of 2006 was $23.3 million and includes $6.4 million of one-time charges related to the r..."
05/01/2006 8-K Quarterly results
Docs: "Alpharma's First Quarter Operating Income Grows 50% EPS of $0.37 from Continuing Operations, Excluding Debt Prepayment Charges Fort Lee, NJ May 1, 2006 Alpharma Inc. , a global specialty pharmaceutical company, announced first quarter diluted earnings per share of $0.62 versus $0.17 a year ago. First quarter 2006 results include $0.49 EPS from discontinued operations, which consists primarily of a $25.8 million after-tax gain on the first quarter 2006 sale of ParMed Pharmaceuticals, Inc., the company's generic pharmaceutical telemarketing distribution business. First quarter 2006 EPS from continuing operations was $0.37, excluding charges of $19.4 related to the prepayment of debt, compared to a diluted loss per share from continuing operations of $0.02 in the first quarter of 2005, exclud..."
11/07/2005 8-K Quarterly results
Docs: "Alpharma Reports Third Quarter 2005 Earnings Per Share of $0.34 17% Revenue Growth, Significant Earnings Improvement, Continued Debt Reduction Fort Lee, NJ November 7, 2005 Alpharma Inc. , a leading global specialty pharmaceutical company, announced third quarter diluted earnings per share of $0.34 versus a loss of $0.09 a year ago. Strong performances in the company's Branded Pharmaceuticals, Animal Health, and U.S. Generics businesses contributed to the significant year-over-year earnings improvement. Third-quarter revenue rose 17% and operating income increased to $36.6 million from $0.3 million in the third quarter of 2004, driven by continued KADIAN prescription growth, increased sales of animal health livestock products, and increased sales of U.S generic products, primarily gabapent..."
08/01/2005 8-K Quarterly results
Docs: "Alpharma Reports Second Quarter 2005 Earnings Per Share of $0.38"
05/05/2005 8-K Quarterly results
Docs: "Alpharma Announces First Quarter 2005 Results"
11/02/2004 8-K Quarterly results
Docs: "Alpharma Announces Third Quarter 2004 Results Full Year 2004 Outlook Updated"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy